INVESTIGATIONS IN THE DESIGN AND CHARACTERIZATION
OF HIV-1 NEUTRALIZING MOLECULES

Thesis by
Joshua Simon Klein

In Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy

California Institute of Technology
Pasadena, California
2009
(Defended May 28, 2009)
This work is dedicated to the memory of my father,

RONALD ALLEN KLEIN

(1947 – 1988)
ACKNOWLEDGEMENTS

It is often said, “There is no ‘I’ in team.” That observation is especially accurate when applied to the work presented in this thesis as it constituted an effort that far exceeded what could be accomplished with one brain and two hands. My graduate experience was blessed by the support of an outstandingly committed and tireless team of research technicians that included Priyanthi Gnanapragasm, Rachel Galimidi, Maria Suzuki, Kathryn Huey-Tubman, and the members of the Protein Expression Center, headed by Dr. Jost Vielmetter, which includes Chris Foglesong, Inder Nagiana, and Michael Anaya. Without their help, this work would have easily taken many more years. In addition to their technical assistance, I am deeply grateful for their support, encouragement, and perennial smiles. My thanks also go to Dr. Anthony West and the rest of my fellow laboratory members, both past and present, whose technical advice has been invaluable.

I am indebted to my advisor, Dr. Pamela J. Björkman, for inviting me to join her laboratory at the inception of this project, for her dedication to the cultivation of my potential as a scientist, and for giving me the freedom to pursue every idea that I felt was worthy of investigation, including the ones that may not have been.

Finally, I would like to express my heartfelt thanks to and admiration for the Bill and Melinda Gates Foundation, whose financial support made this work possible.
Human Immunodeficiency Virus (HIV) is a T-lymphotrophic retrovirus that is the causative agent of Acquired Immunodeficiency Syndrome and is estimated to currently infect approximately 40 million people worldwide. Life-extending therapies are credited for the precipitous drop in HIV-related mortality in developed countries, but their high costs prevent widespread distribution in developing countries. To date, all attempts to produce a vaccine capable of preventing or controlling an HIV infection have failed, but a comprehensive explanation for these failures has yet to emerge from the available data. In this thesis the first chapter provides an overview of the pandemic, the antigenic properties of gp120 and gp41, which are the two glycoproteins that comprise the outer envelope spike of the virus, and the broadly neutralizing antibodies that have been isolated against them. The second and third chapters discuss biophysical characterizations of these monoclonal antibodies and newly designed molecules derived from them. Based on a comparison of these data with pre-existing research, a novel hypothesis called the “island effect” was developed and is presented as a possible explanation for the consistent failure of the human immune system to respond to infection or vaccination with an effective humoral response. The final chapter summarizes ongoing investigations in the capacities of broadly neutralizing monoclonal antibodies to recruit antibody-dependent cellular cytotoxicity, a mechanism by which antibodies can trigger the lysis of HIV-infected cells by the innate immune system.
# Table of Contents

**Acknowledgements** ........................................................................................................ iv

**Abstract** ................................................................................................................................... v

**Chapter 1:**
- Introduction .......................................................................................................................... 1

**Chapter 2:**

**Chapter 3:**
- Assessing the impact of HIV spike arrangement on antibody avidity ............................... 49

**Chapter 4:**
- Potent neutralization of HIV is not a predictor of the ability to trigger antibody-dependent cellular cytotoxicity .................................................................................................................. 88

**Appendix A:**
- Software: *VictorExtract* and *GraphExtract* .................................................................. 110

**Appendix B:**
- Listing of designed anti-HIV-1 molecules .......................................................................... 119

**Appendix C:**
APPENDIX D:

APPENDIX E:

APPENDIX F:
LIST OF FIGURES AND TABLES

CHAPTER 1:

Figure 1. X-ray crystal structures of envelope spike proteins ...........................................12

Figure 2. Schematic model of the HIV envelope spike fusion mechanism ......................15

Figure 3. Models of the HIV envelope spike bound to CD4 and monoclonal antibodies ..........................................................18

CHAPTER 2:

Figure 1. Structures of antibody constructs .................................................................33

Figure 2. Biophysical characterization of the antibody constructs ..................................34

Figure 3. Bar graph of ratios of average molar IC$_{50}$ values (arithmetic means) for b12 constructs (blue) and 4E10 constructs (orange) ...............................................................35

Figure S1. Surface plasmon resonance sensorgrams for binding to immobilized antigens ..................................................................................................................41

Figure S2. In vitro pseudovirus neutralization curves ......................................................42

Figure S3. Modeling of the structural requirements for IgG b12 to achieve intra-spike cross-linking .........................................................................................................44

Figure S4. Bar graph of ratios of average molar IC$_{50}$ values (geometric means) for b12 constructs (blue) and 4E10 constructs (orange) ..................................................45

Table 1. Strain-specific IC$_{50}$ neutralization values (nM) for each antibody construct ..........................................................................................................................35

Table S1. Strain-specific IC$_{50}$ neutralization ratios .......................................................46

Table S2. IgG b12 and scFv b12 were used as internal controls to examine the reproducibility of independently determined IC$_{50}$ values ...........................................47

Table S3. Comparison of IC$_{50}$ values for IgG b12 and IgG 4E10 to previously published results .................................................................................................................48

CHAPTER 3:

Figure 1. IC$_{50}$ values for the neutralization of various strains of HIV from clades B and C using b12 ...........................................................................................................52
Figure 2. Modeling the dissociation to B from AB (Fab) and AB₂ (IgG) ...............56

Figure 3. Comparison of IC₅₀ neutralization values for antibodies as Fabs and intact IgGs.................................................................59

Figure 4. Comparison of neutralization potencies for Palivizumab and affinity-improved mutants with slower intrinsic dissociation constants (reported in (15)).......59

Figure 5. Available structures of enveloped viruses showing spike densities derived by electron microscopy.................................................61

Figure 6. Protein fusion linker candidates and models........................................64

Figure 7. Schematic of the structure of a human IgG antibody of subclass 1 with RCEs, reduced SDS PAGE results for IgG b12 with Gly₄Ser RCEs, and gel filtration profile of IgG 2G12 (G₄S)₁.........................................................66

Figure 8. SPR dissociation curves for Fab, IgG, and IgG (G₄S)₅ constructs bound to immobilized monomeric gp120 (b12 and 2G12) or immobilized gp41 (4E10 and 2F5)........................................................................68

Figure 9. Results of the in vitro neutralization assay comparing wild type IgG constructs with RCEs..................................................................69

Figure 10. Reduced SDS PAGE analysis of IgGs that were successfully expressed with PFEs after purification by SEC......................................................72

Figure 11. Gel filtrations profiles for IgGs with protein fusion extensions............73

Figure 12. Dissociation curves for PFE constructs and 2G12 dimer bound to immobilized monomeric gp120 (2G12) or immobilized gp41 (4E10 and 2F5)........74

Figure 13. Comparison of neutralization activities for PFEs versus wild type IgGs (HIV strain 6535.3) .................................................................................75

Table 1. Half-life values (t₁/₂) of antibody-antigen complexes calculated from models presented in Fig. 2 .................................................................56

Table 2. Protein yields for 1 L expressions of each of the RCE constructs..........66

Table 3. Half-life times (t₁/₂) calculated from dissociation curves in Fig. 8........68

Table 4. Half-life times (t₁/₂) calculated from the dissociation curves of dimeric IgG 2G12 and PFEs in Fig. 11.................................................................74
CHAPTER 4:

Figure 1. Four cell lines examined for stable surface expression of gp160..............93

Figure 2. Summary of curves for the in vitro neutralization data and *in vitro* ADCC data..........................................................96

Figure 3. Summary of curves from the in vitro ADCC data for control tests of IgG1 2G12 monomer and dimer versus untransfected CHO cells .........................97

Figure 4. Model structure of IgG-CD16 complex ..............................................100

Figure 5. Conceptual model of the distance requirements for simultaneous binding of IgG1 with CD16 and the HIV envelope spike with the assumption that the 16-residue unstructured linker connecting the extracellular domains of CD16 to the membrane is adopting a fully extended state........................................101

Table 1. Summary of calculated 50% effective doses (ED50) for specific lysis in the in vitro ADCC assay and 50% inhibitory concentrations (IC50) for the in vitro neutralization assay .................................................................97